The effects of revised peer-counselor support on the PMTCT cascade of care: results from a cluster-randomized trial in Kenya (the EMMA study)

Table 2 Proportion of days covered (PDC) with antiretroviral medications^a

Outcome	SC	INT	RD (Crude)^a	RD (Crude 2)	RD (Adjusted)
	SC	INT	(95% CI)	(95% CI)	(95% CI)
	N = 151	N = 158	N = 309 (151/158)	N = 290 (144/146)	N = 290 (144/146)
PO1: At least 0.90 PDC during last 24 weeks of pregnancy at least 0.90	0.32	0.25	-0.07	-0.07	-0.05
			(-0.223, 0.063)	(-0.217, 0.049)	(-0.176, 0.095)
PO2: At least 0.90 PDC first 24 weeks postpartum	0.30	0.31	0.01	0.02	0.12
PO2: At least 0.90 PDC first 24 weeks postpartum			(-0.145, 0.159]	(-0.154, 0.171)	(-0.046, 0.284)

^a RD = Risk difference. Crude uses the full sample (309 for mother outcomes, for infant HIV testing outcomes). Crude 2 excludes those without mother age or weeks gestation at the first ANC visit (used in the adjusted model). Adjusted reports risk differences adjusted for baseline covariates: mother's age, weeks gestation at first ANC visit, Mentor Mothers new at the site, site follow up period overlapped with nurses strike

ISSN: 1471-2334